NYSE to delist Ginkgo Bioworks warrants for abnormally low price; common stock regains compliance

Ginkgo Bioworks Holdings, Inc.

NYSE notified Ginkgo on Sept 3, 2024 to delist warrants (DNA.WS) due to 'abnormally low' trading prices; trading suspended immediately.
Common stock (DNA) unaffected and continues trading normally on NYSE.
Ginkgo regained compliance with NYSE minimum price rule on Aug 30, 2024; closing price above $1.00 for 30-day average.
Company removed from NYSE noncompliant issuers list for common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.